Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Andrew Blauvelt, Nianwen Shi, Russel Burge, William N Malatestinic, Chen-Yen Lin, Carolyn R Lew, Nicole M Zimmerman, Orin M Goldblum, Baojin Zhu & Mwangi J Murage. (2020) Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab. Patient Preference and Adherence 14, pages 517-527.
Read now
Read now
Jashin J. Wu, Corey Pelletier, Brian Ung & Marc Tian. (2020) Treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysis. Current Medical Research and Opinion 36:1, pages 169-176.
Read now
Read now
Sara Higa, Beth Devine, Vaishali Patel, Sarah Baradaran, Degang Wang & Aasthaa Bansal. (2019) Psoriasis treatment patterns: a retrospective claims study. Current Medical Research and Opinion 35:10, pages 1727-1733.
Read now
Read now
Hélène Roche, Kevin Bouiller, Eve Puzenat, Elise Deveza, Blandine Roche, Fabien Pelletier, Alison van de Laak, Anne Sophie Dupond, Charlée Nardin & François Aubin. (2019) Efficacy and survival of biologic agents in psoriasis: a practical real-life 12-year experience in a French dermatology department. Journal of Dermatological Treatment 30:6, pages 540-544.
Read now
Read now
Mwangi J. Murage, David M. Kern, Lawrence Chang, Kalyani Sonawane, William N. Malatestinic, Ralph A. Quimbo, Steven R. Feldman, Talia M. Muram & Andre B. Araujo. (2019) Treatment patterns among patients with psoriasis using a large national payer database in the United States: a retrospective study. Journal of Medical Economics 22:1, pages 53-62.
Read now
Read now
Mwangi J Murage, Vanita Tongbram, Steven R Feldman, William N Malatestinic, Cynthia J Larmore, Talia M Muram, Russel T Burge, Charles Bay, Nicole Johnson, Sarah Clifford & Andre B Araujo. (2018) Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review. Patient Preference and Adherence 12, pages 1483-1503.
Read now
Read now
Daniel J. No, Megan S. Inkeles, Mina Amin & Jashin J. Wu. (2018) Drug survival of biologic treatments in psoriasis: a systematic review. Journal of Dermatological Treatment 29:5, pages 460-466.
Read now
Read now
Articles from other publishers (29)
Tanja Heidbrede, Antje Mevius, Sebastian Kessel, Thomas Wilke, Ulf Maywald & Alexander Thiem. (2023) Systemische Behandlung von Patienten mit Psoriasis in der täglichen Praxis: Eine retrospektive Studie auf Basis deutscher Krankenkassendaten. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 21:6, pages 611-621.
Crossref
Crossref
Tanja Heidbrede, Antje Mevius, Sebastian Kessel, Thomas Wilke, Ulf Maywald & Alexander Thiem. (2023) Real‐world systemic treatment of patients with psoriasis: A retrospective study based on German claims data. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 21:6, pages 611-619.
Crossref
Crossref
Delia Colombo, Micol Frassi, Giusy Pagano Mariano, Enrico Fusaro, Claudia Lomater, Patrizia Del Medico, Florenzo Iannone, Rosario Foti, Massimiliano Limonta, Antonio Marchesoni, Bernd Raffeiner, Ombretta Viapiana, Walter Grassi, Rosa Daniela Grembiale, Giuliana Guggino, Antonino Mazzone, Enrico Tirri, Roberto Perricone, Pier Carlo Sarzi Puttini, Salvatore De Vita, Fabrizio Conti, Alessandra Ori, Lucia Simoni, Martina Fiocchi, Roberto Orsenigo, Emanuela Zagni, Micol Frassi, Maurizio Caminiti, Enrico Fusaro, Claudia Lomater, Patrizia Del Medico, Florenzo Iannone, Rosario Foti, Massimiliano Limonta, Antonio Marchesoni, Bernd Raffeiner, Ombretta Viapiana, Walter Grassi, Rosa Daniela Grembiale, Giuliana Guggino, Antonino Mazzone, Enrico Tirri, Roberto Perricone, Pier Carlo Sarzi Puttini, Salvatore De Vita & Fabrizio Conti. (2022) Real-world evidence of biologic treatments in psoriatic arthritis in Italy: results of the CHRONOS (EffeCtiveness of biologic treatments for psoriatic artHRitis in Italy: an ObservatioNal lOngitudinal Study of real-life clinical practice) observational longitudinal study. BMC Rheumatology 6:1.
Crossref
Crossref
Philip J. Mease, Pamela Young, David Gruben, Lara Fallon, Rebecca Germino & Arthur Kavanaugh. (2022) Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database. Advances in Therapy 39:6, pages 2932-2945.
Crossref
Crossref
Eugenia Piragine, Davide Petri, Alma Martelli, Agata Janowska, Valentina Dini, Marco Romanelli, Vincenzo Calderone & Ersilia Lucenteforte. (2022) Adherence and Persistence to Biological Drugs for Psoriasis: Systematic Review with Meta-Analysis. Journal of Clinical Medicine 11:6, pages 1506.
Crossref
Crossref
Egídio Freitas, Andrew Blauvelt & Tiago Torres. (2021) Bimekizumab for the Treatment of Psoriasis. Drugs 81:15, pages 1751-1762.
Crossref
Crossref
Kim A. Papp, Ahmed M. Soliman, Nicolae Done, Christopher Carley, Esteban Lemus Wirtz & Luis Puig. (2021) Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model. Dermatology and Therapy 11:4, pages 1291-1304.
Crossref
Crossref
Martin Bergman, Pankaj Patel, Naijun Chen, Yonghua Jing & Christopher D. Saffore. (2020) Evaluation of Adherence and Persistence Differences Between Adalimumab Citrate-Free and Citrate Formulations for Patients with Immune-Mediated Diseases in the United States. Rheumatology and Therapy 8:1, pages 109-118.
Crossref
Crossref
Kenneth B Gordon, Peter Foley, James G Krueger, Andreas Pinter, Kristian Reich, Ronald Vender, Veerle Vanvoorden, Cynthia Madden, Katy White, Christopher Cioffi & Andrew Blauvelt. (2021) Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. The Lancet 397:10273, pages 475-486.
Crossref
Crossref
Andrew Blauvelt, Craig L. Leonardi, Melinda Gooderham, Kim A. Papp, Sandra Philipp, Jashin J. Wu, Atsuyuki Igarashi, Mary Flack, Ziqian Geng, Tianshuang Wu, Anne Camez, David Williams & Richard G. Langley. (2020) Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis. JAMA Dermatology 156:6, pages 649.
Crossref
Crossref
Kurt R Oelke, Olivier Chambenoit, Amar Q Majjhoo, Stephani Gray, Kate Higgins & Peter Hur. (2019) Persistence and adherence of biologics in US patients with psoriatic arthritis: analyses from a claims database. Journal of Comparative Effectiveness Research 8:8, pages 607-621.
Crossref
Crossref
Steven R. FeldmanHaijun TianXinyue WangRebecca Germino. (2019) Health Care Utilization and Cost Associated with Biologic Treatment Patterns Among Patients with Moderate to Severe Psoriasis: Analyses from a Large U.S. Claims Database. Journal of Managed Care & Specialty Pharmacy 25:4, pages 479-488.
Crossref
Crossref
Pei-Tzu Lin, Shu-Hui Wang & Ching-Chi Chi. (2018) Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence. Scientific Reports 8:1.
Crossref
Crossref
Nikos Maniadakis, Emese Toth, Michael Schiff, Xuan Wang, Maria Nassim, Boglarka Szegvari, Irina Mountian & Jeffrey R. Curtis. (2018) A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences. Advances in Therapy 35:9, pages 1333-1355.
Crossref
Crossref
Frank Behrens, Lothar Meier, Jörg C. Prinz, Jürgen Jobst, Ralph Lippe, Peter-Andreas Löschmann & Hanns-Martin Lorenz. (2018) Simultaneous Response in Several Domains in Patients with Psoriatic Disease Treated with Etanercept as Monotherapy or in Combination with Conventional Synthetic Disease-modifying Antirheumatic Drugs. The Journal of Rheumatology 45:6, pages 802-810.
Crossref
Crossref
Antonio Costanzo, Giovanna Malara, Claudio Pelucchi, Francesco Fatiga, Giovanna Barbera, Andrea Franchi & Carlotta Galeone. (2018) Effectiveness End Points in Real-World Studies on Biological Therapies in Psoriasis: Systematic Review with Focus on Drug Survival. Dermatology 234:1-2, pages 1-12.
Crossref
Crossref
Luisa Costa, Carlo Perricone, Maria Sole Chimenti, Antonio Del Puente, Paolo Caso, Rosario Peluso, Paolo Bottiglieri, Raffaele Scarpa & Francesco Caso. (2017) Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence. Drugs in R&D 17:4, pages 509-522.
Crossref
Crossref
Júlia Vide & Sofia Magina. (2017) Moderate to severe psoriasis treatment challenges through the era of biological drugs. Anais Brasileiros de Dermatologia 92:5, pages 668-674.
Crossref
Crossref
Joseph F. Merola, Benjamin Lockshin & Elinor A. Mody. (2017) Switching biologics in the treatment of psoriatic arthritis. Seminars in Arthritis and Rheumatism 47:1, pages 29-37.
Crossref
Crossref
I.Y.K. Iskandar, D.M. Ashcroft, R.B. Warren, I. Evans, K. McElhone, C.M. Owen, A.D. Burden, C.H. Smith, N.J. Reynolds & C.E.M. Griffiths. (2017) Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). British Journal of Dermatology 176:5, pages 1297-1307.
Crossref
Crossref
Kristian Reich, April W. Armstrong, Peter Foley, Michael Song, Yasmine Wasfi, Bruce Randazzo, Shu Li, Y.-K. Shen & Kenneth B. Gordon. (2017) Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial. Journal of the American Academy of Dermatology 76:3, pages 418-431.
Crossref
Crossref
Philip J. Mease, Tamara Lesperance, Mei Liu, David H. Collier, Marc Mason, Sabrina Deveikis & Neil A. Accortt. (2017) Changes in Treatment Patterns in Patients with Psoriatic Arthritis Initiating Biologic and Nonbiologic Therapy in a Clinical Registry. The Journal of Rheumatology 44:2, pages 184-192.
Crossref
Crossref
James Harnett, Robert Gerber, David Gruben, Andrew S. KoenigConnie Chen. (2016) Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database. Journal of Managed Care & Specialty Pharmacy 22:12, pages 1457-1471.
Crossref
Crossref
A. Menter, K.A. Papp, M. Gooderham, D.M. Pariser, M. Augustin, F.A. Kerdel, S. Fakharzadeh, K. Goyal, S. Calabro, W. Langholff, S. Chavers, D. Naessens, J. Sermon & G.G. Krueger. (2016) Drug survival of biologic therapy in a large, disease‐based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Journal of the European Academy of Dermatology and Venereology 30:7, pages 1148-1158.
Crossref
Crossref
Jalpa A. Doshi, Junko Takeshita, Lionel Pinto, Penxiang Li, Xinyan Yu, Preethi Rao, Hema N. Viswanathan & Joel M. Gelfand. (2016) Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population. Journal of the American Academy of Dermatology 74:6, pages 1057-1065.e4.
Crossref
Crossref
Dominika Wcisło-Dziadecka, Martyna Zbiciak-Nylec, Ligia Brzezińska-Wcisło & Urszula Mazurek. (2016) TNF-α in a molecularly targeted therapy of psoriasis and psoriatic arthritis. Postgraduate Medical Journal 92:1085, pages 172-178.
Crossref
Crossref
F. Behrens, J. D. Canete, I. Olivieri, A. W. van Kuijk, N. McHugh & B. Combe. (2014) Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature. Rheumatology 54:5, pages 915-926.
Crossref
Crossref
Lívia Lovato Pires Lemos, Juliana de Oliveira Costa, Alessandra Maciel Almeida, Haliton Oliveira Junior, Mariana Michel Barbosa, Adriana Maria Kakehasi & Francisco Assis Acurcio. (2014) Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety. Rheumatology International 34:10, pages 1345-1360.
Crossref
Crossref
Lesley J. Scott. (2014) Etanercept: A Review of Its Use in Autoimmune Inflammatory Diseases. Drugs 74:12, pages 1379-1410.
Crossref
Crossref